IOL Chemicals and Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Wed Apr 22 2026

IOL Chemicals and Pharmaceuticals (IOLCP) Q4 FY26 results are expected on May 2026. Analyst consensus estimates revenue at Rs 680–760 Cr and PAT at Rs 48–65 Cr for the January to March 2026 quarter. This article covers what analysts are expecting, five key growth factors to watch, risks to the investment thesis, and a complete FAQ section for investors.

Click Here — Get Free SEBI-registered Research on IOL Chemicals and Pharmaceuticals on Univest.

Table of Contents

IOL Chemicals and Pharmaceuticals Q4 FY26 Results Overview

Company	IOL Chemicals and Pharmaceuticals
NSE Ticker	IOLCP
Sector	API / Ibuprofen / Specialty Chemicals
CMP (April 2026)	Rs 380
52-Week High	Rs 580
52-Week Low	Rs 295
Q4 FY26 Results Date	May 2026
Revenue Estimate	Rs 680–760 Cr
PAT Estimate	Rs 48–65 Cr
Key Margin Metric	EBITDA 9–12%

Data from NSE/BSE and analyst estimates. April 2026. Verify before investing.

Track live IOL Chemicals and Pharmaceuticals price and analyst targets on the Univest Screener.

What to Expect from IOL Chemicals and Pharmaceuticals Q4 FY26

Get Free Investment Predictions on Univest — Tap Here.

IOL Chemicals and Pharmaceuticals is expected to report Q4 FY26 results on May 2026. The board meeting will consider the financial results for the quarter ended March 31, 2026. Revenue is estimated at Rs 680–760 Cr and PAT at Rs 48–65 Cr, with EBITDA 9–12% as the key operational metric. India’s Q4 FY26 earnings season runs through April and May 2026, with the Nifty 50 aggregate PAT growth expected at 8 to 12 percent YoY. Key themes across the season include margin recovery, capex normalisation, and FY27 guidance.

Budget 2026-27 Impact on API

Union Budget 2026-27 continued strong support for the API sector through PLI scheme continuation, infrastructure capex of Rs 11.21 lakh crore, and consumption-led demand incentives. The US 26 percent reciprocal tariff announced April 2, 2026 has created FII outflow pressure across Indian equities, but domestic policy support provides a buffer for IOL Chemicals and Pharmaceuticals’s core business segments heading into Q4 FY26.

Q4 FY26 Estimates Table

Metric	Q4 FY26 Estimate	Q4 FY25 Actual	YoY Change
Revenue	Rs 680–760 Cr	Verify on NSE	10–15% YoY est
PAT	Rs 48–65 Cr	Verify on NSE	12–18% YoY est
EBITDA	EBITDA 9–12%	Verify on NSE	Stable to improving

Estimates from analyst consensus. Actual results may differ. Verify before investing.

5 Key Growth Factors to Watch in IOL Chemicals and Pharmaceuticals Q4 FY26 Results

1. US Generics Revenue and Market Share

Analysts tracking IOL Chemicals and Pharmaceuticals will monitor US Generics Revenue and Market Share closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

2. Domestic Branded Formulations Volume

Analysts tracking IOL Chemicals and Pharmaceuticals will monitor Domestic Branded Formulations Volume closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

3. API Business Margin Recovery

Analysts tracking IOL Chemicals and Pharmaceuticals will monitor API Business Margin Recovery closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

4. FDA Inspection Status

Analysts tracking IOL Chemicals and Pharmaceuticals will monitor FDA Inspection Status closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

5. R&D Pipeline and ANDA Filings

Analysts tracking IOL Chemicals and Pharmaceuticals will monitor R&D Pipeline and ANDA Filings closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

Download the Univest iOS App or Android App for live Q4 FY26 results alerts and SEBI-registered analyst research on IOL Chemicals and Pharmaceuticals.

5 Risk Factors for IOL Chemicals and Pharmaceuticals Investors

1. FDA Warning Letter or Import Alert Risk

FDA Warning Letter or Import Alert Risk is a key monitorable for IOL Chemicals and Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

2. US Generics Price Erosion — 5 to 8 percent Annual

US Generics Price Erosion — 5 to 8 percent Annual is a key monitorable for IOL Chemicals and Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

3. R&D Pipeline Failure or Delay

R&D Pipeline Failure or Delay is a key monitorable for IOL Chemicals and Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

4. Emerging Market Currency Volatility

Emerging Market Currency Volatility is a key monitorable for IOL Chemicals and Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

5. Domestic Pricing Regulation — DPCO

Domestic Pricing Regulation — DPCO is a key monitorable for IOL Chemicals and Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

Analyst Ratings and Targets for IOL Chemicals and Pharmaceuticals

Brokerage	Rating	12M Target	Thesis
MOFSL	Buy	Rs 456	FY27 earnings recovery; API sector leadership
YES Securities	Buy	Rs 463	Quality execution; accumulate at support
Kotak Institutional	Add	Rs 436	Monitor Q4 FY26 result vs estimates closely
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity

Analyst targets are estimates as of April 2026. These are not guaranteed returns. Verify before investing.

Subscribe to Univest Pro for SEBI-registered analyst entry, target, and stop-loss recommendations.

Q4 FY26 Earnings Calendar — Other Major Companies

Company	Results Date
Infosys	Apr 23, 2026
IndusInd Bank	Apr 24, 2026
InterGlobe Aviation (IndiGo)	Apr 28, 2026
IOL Chemicals and Pharmaceuticals	May 2026

For the full Q4 FY26 results calendar, visit Univest Blogs.

Discover API stocks with strong Q4 FY26 performance on the Univest Screener.

Conclusion

IOL Chemicals and Pharmaceuticals (IOLCP) Q4 FY26 results on May 2026 are a key earnings event for investors in the API / Ibuprofen / Specialty Chemicals sector. Analyst consensus expects revenue of Rs 680–760 Cr and PAT of Rs 48–65 Cr. A beat versus estimates supports the bull case for re-rating toward analyst targets. A miss increases downside risk. Monitor results live and get instant research alerts on the Univest Screener or the Univest App. For more Q4 FY26 results previews, visit Univest Blogs.

Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. All analyst estimates and targets are sourced from publicly available research and may change. Verify all numbers on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: When is IOL Chemicals and Pharmaceuticals Q4 FY26 results date?

IOL Chemicals and Pharmaceuticals Q4 FY26 results are expected on May 2026. The board meeting will consider the quarterly financials for January to March 2026. Track the announcement on NSE or the Univest Screener.

Q: What is IOL Chemicals and Pharmaceuticals Q4 FY26 revenue estimate?

Analyst consensus estimates IOL Chemicals and Pharmaceuticals Q4 FY26 revenue at Rs 680–760 Cr. Actual results may differ. Verify with MOFSL, YES Securities, or Kotak research once declared on May 2026.

Q: What is IOL Chemicals and Pharmaceuticals Q4 FY26 PAT estimate?

Analyst consensus expects IOL Chemicals and Pharmaceuticals Q4 FY26 PAT at Rs 48–65 Cr. This is an estimate based on publicly available research — actual results may vary. Track results live on the Univest Screener.

Q: Is IOL Chemicals and Pharmaceuticals a buy before Q4 FY26 results?

This article does not constitute investment advice. Investors should review actual Q4 FY26 results before making investment decisions. A beat versus estimates typically supports price recovery; a miss increases downside risk. Consult a SEBI-registered financial advisor.

Q: What is IOL Chemicals and Pharmaceuticals current share price?

IOL Chemicals and Pharmaceuticals (NSE: IOLCP) is trading at Rs 380 as of April 2026. Track the live price, FII or DII flows, and analyst ratings on the Univest Screener at univest.in/screeners.

Q: What are the key factors to watch in IOL Chemicals and Pharmaceuticals Q4 FY26?

Key factors for IOL Chemicals and Pharmaceuticals Q4 FY26 include: US Generics Revenue and Market Share, Domestic Branded Formulations Volume, API Business Margin Recovery. Track all these metrics on the Univest Screener.

Q: What is IOL Chemicals and Pharmaceuticals FY27 outlook?

Analyst consensus expects IOL Chemicals and Pharmaceuticals to deliver 12 to 18 percent earnings growth in FY27 — contingent on macro stabilisation, sector tailwinds, and execution on the growth plan outlined in Q4 FY26 management commentary.

Q: Where to track IOL Chemicals and Pharmaceuticals Q4 FY26 results live?

Track IOL Chemicals and Pharmaceuticals Q4 FY26 results live on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for instant research alerts when results are declared on May 2026.